S Michels

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Is intravitreal bevacizumab (Avastin) safe?
    S Michels
    Br J Ophthalmol 90:1333-4. 2006
  2. doi [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]
    S Michels
    Ophthalmology, University Hospital Zurich
    Klin Monbl Augenheilkd 225:292-4. 2008
  3. doi Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium
    S Michels
    Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, 8091 Zurich, Switzerland
    Br J Ophthalmol 92:204-9. 2008
  4. doi [Age-related macular degeneration (AMD)]
    Stephan Michels
    Augenklinik, Universitatsspital Zurich
    Ther Umsch 66:189-95. 2009
  5. doi Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
    K Kriechbaum
    University Eye Hospital Zurich, Frauenklinikstrasse 24, CH 8091 Zurich, Switzerland
    Br J Ophthalmol 92:518-22. 2008
  6. doi Intravitreal anti-VEGF therapy for retinal macroaneurysm
    S A Zweifel
    University Hospital Zurich, Department of Ophthalmology, Zurich, Switzerland
    Klin Monbl Augenheilkd 230:392-5. 2013
  7. doi Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders
    M Menghini
    University Hospital of Zurich, Department of Ophthalmology, Zurich, Switzerland
    Klin Monbl Augenheilkd 227:244-8. 2010
  8. doi Multimodal imaging of autosomal dominant drusen
    S A Zweifel
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
    Klin Monbl Augenheilkd 229:399-402. 2012
  9. doi Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study
    S Sacu
    Medical University of Vienna, Department of Ophthalmology, Vienna, Austria
    Br J Ophthalmol 92:1347-51. 2008
  10. doi Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
    G Weigert
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Br J Ophthalmol 92:356-60. 2008

Collaborators

Detail Information

Publications21

  1. pmc Is intravitreal bevacizumab (Avastin) safe?
    S Michels
    Br J Ophthalmol 90:1333-4. 2006
  2. doi [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]
    S Michels
    Ophthalmology, University Hospital Zurich
    Klin Monbl Augenheilkd 225:292-4. 2008
    ..Intravitreal injections of anti-VEGF drugs might provide a new therapeutic option in this condition...
  3. doi Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium
    S Michels
    Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, 8091 Zurich, Switzerland
    Br J Ophthalmol 92:204-9. 2008
    ..To evaluate pathological changes of retinal pigment epithelium (RPE) by polarisation-sensitive optical coherence tomography (PS-OCT)...
  4. doi [Age-related macular degeneration (AMD)]
    Stephan Michels
    Augenklinik, Universitatsspital Zurich
    Ther Umsch 66:189-95. 2009
    ..Significant progress has been made in the treatment of the neovascular form of the disease using inhibitors of the vascular endothelial growth factor (VEGF)...
  5. doi Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
    K Kriechbaum
    University Eye Hospital Zurich, Frauenklinikstrasse 24, CH 8091 Zurich, Switzerland
    Br J Ophthalmol 92:518-22. 2008
    ..To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO)...
  6. doi Intravitreal anti-VEGF therapy for retinal macroaneurysm
    S A Zweifel
    University Hospital Zurich, Department of Ophthalmology, Zurich, Switzerland
    Klin Monbl Augenheilkd 230:392-5. 2013
    ..We evaluated the effect of intravitreal anti-vascular endothelial growth factor therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation...
  7. doi Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders
    M Menghini
    University Hospital of Zurich, Department of Ophthalmology, Zurich, Switzerland
    Klin Monbl Augenheilkd 227:244-8. 2010
    ..While some patients show a good response (increase in VA), others disclose much less promising results...
  8. doi Multimodal imaging of autosomal dominant drusen
    S A Zweifel
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
    Klin Monbl Augenheilkd 229:399-402. 2012
    ..This case series describes the morphological features of drusen associated with ML using multimodal imaging...
  9. doi Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study
    S Sacu
    Medical University of Vienna, Department of Ophthalmology, Vienna, Austria
    Br J Ophthalmol 92:1347-51. 2008
    ..To compare early treatment effect of reduced fluence versus standard photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in neovascular age-related macular degeneration...
  10. doi Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
    G Weigert
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Br J Ophthalmol 92:356-60. 2008
    ....
  11. ncbi [Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]
    W Geitzenauer
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Allgemeines Krankenhaus, Wien
    Klin Monbl Augenheilkd 223:822-7. 2006
    ..The purpose of this study was to evaluate the early treatment response following systemic and intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD)...
  12. ncbi [Paravenous changes in the retinal pigment epithelium]
    S Michels
    Klinik fur Augenheilkunde, Medizinischen Universität zu Lübeck
    Ophthalmologe 99:206-7. 2002
  13. ncbi [Expression of angiogenic factors by photodynamic therapy]
    M Rudolf
    Universitatsklinikum Schleswig Holstein, Augenklinik Campus Kiel
    Klin Monbl Augenheilkd 221:1026-32. 2004
    ..The purpose of this study was to evaluate the impact of photodynamic therapy (PDT) on the regulation of angiogenic factors such as vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) in human eyes...
  14. ncbi [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]
    S Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Osterreich
    Klin Monbl Augenheilkd 222:480-4. 2005
    ..Anti-VEGF therapy using Ranibizumab is a promising new treatment option for neovascular AMD...
  15. ncbi Topographic angiography and optical coherence tomography: a correlation of imaging characteristics
    C Ahlers
    University Eye Hospital Vienna, Vienna, Austria
    Eur J Ophthalmol 15:774-81. 2005
    ..OCT and TAG imaging were compared to specify the characteristics of each imaging modality...
  16. ncbi Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration
    U Schmidt-Erfurth
    Department of Ophthalmology, University of Vienna, Vienna Austria
    Eur J Ophthalmol 15:482-5. 2005
    ..As part of this trial, 128 patients with subfoveal choroidal neovascularization (CNV) secondary to ARMD were enrolled and treated for up to 2 years by 18 clinical sites in the United States and European Union...
  17. ncbi Photodynamic therapy with verteporfin: a new treatment in ophthalmology
    S Michels
    University Eye Hospital, , Germany
    Semin Ophthalmol 16:201-6. 2001
    ..This review summarizes the mechanisms of action of PDT, and the results of preclinical and clinical studies in ophthalmology...
  18. ncbi [Three-dimensional imaging of photodynamic effects and spontaneous course in choroidal neovascularization]
    W Ahlswede
    Augenklinik, Universitatsklinikum Schleswig Holstein, Lubeck
    Ophthalmologe 101:675-81. 2004
    ..The process of vascular alteration is documented quantitatively and qualitatively by three-dimensional angiography...
  19. ncbi [Chorioretinal anastomosis as unfavourable prognostic factor during photodynamic therapy]
    C Kusserow
    Universitäts Augenklinik Lübeck
    Ophthalmologe 100:197-202. 2003
    ..The aim of this study was the documentation of chorioretinal anastomosis in neovascular age-related macular degeneration (AMD) and correlation with functional and angiographic results following photodynamic therapy (PDT)...
  20. ncbi [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]
    R Hahn
    Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Wien, Osterreich
    Ophthalmologe 104:588-93. 2007
    ..The aim of this study was to compare intravitreal bevacizumab (IVB) and verteporfin therapy in combination with 4 mg intravitreal triamcinolone (PDT-IVTA) in patients with neovascular age-related macular degeneration (AMD)...
  21. ncbi [Changes in neovascular membranes and normal choroid blood vessels after multiple photodynamic therapy treatments]
    S Michels
    Universitätsaugenklinik Lübeck, Ratzeburger Allee 160, 23538 Lubeck
    Ophthalmologe 99:96-100. 2002
    ..ICG angiography (ICGA) was used to document the effect of repeated PDT (verteporfin) on size and leakage of choroidal neovascularisation in age-related macular degeneration (AMD) and treatment-related side effects on the choroid...